Side-by-side · Research reference

HGH Fragment 176-191vsSemax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED28/59 cited

BHuman-MechanisticAUTO-DRAFTED12/39 cited

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

Semax

Cognitive enhancer · Russian Pharma

200–600 mcg/doseIntranasalKaplan 2017

HumanMechanisticKaplan 2017

~30 minOnset

Intranasal · 2–3×/day during cognitive demand

01Mechanism of Action

Parameter

HGH Fragment 176-191

Semax

Primary target

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

BDNF / NGF expression + monoamine modulationKaplan 2017

Pathway

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017

Downstream effect

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017

Feedback intact?

N/A — does not interact with GH/IGF-1 axis

—

Origin

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017

Antibody development

Not reported in available studies

—

02Dosage Protocols

Parameter

HGH Fragment 176-191

Semax

Animal dose (oral)

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

—

Animal dose (IP)

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

—

Human equivalent dose

Not established — no published human RCTs

—

Frequency

Once daily (animal models)

2–3× per day during cognitive demand

Evidence basis

Animal studies only

Human-mechanistic + Russian clinicalKaplan 2017

Duration tested

14–19 daysHeffernan 2001 Ng 2000

—

Detection window

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

—

Oral bioavailability

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

—

Standard dose

—

200–600 mcg / dose intranasalKaplan 2017

Lower / starter dose

—

100 mcg / dose

Duration

—

10–14 day cycles, repeated PRN

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon

Half-life

—

Short plasma; CNS effect lasts ~3–6 hr

03Metabolic / Fat Loss Evidence

Parameter

HGH Fragment 176-191

Semax

Primary fat target

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

—

Weight gain reduction

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

—

Body fat reduction

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

—

Lipolytic activity

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

—

Beta-3 AR expression

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

—

Insulin sensitivity

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

—

IGF-1 impact

No elevation — fragment does not activate GH/IGF-1 axis

—

Beta-3 AR dependency

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

—

Route of administration

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

—

Human evidence

None published — pre-clinical only

—

04Side Effects & Safety

Parameter

HGH Fragment 176-191

Semax

Insulin sensitivity

No adverse effects observed in euglycemic clamp (animal)Ng 2000

—

GH/IGF-1 axis

No activation — avoids diabetogenic effects of full GHNg 2000

—

Human safety data

Not available — no published human trials

—

WADA status

Banned as performance-enhancing drugCox 2015

—

Metabolic profile

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

—

Nasal irritation

—

Mild burning or congestion (transient)

Sleep disruption

—

Late-day dosing may interfere with sleep

Headache

—

Uncommon, transient

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Absolute Contraindications

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

Semax

·Pregnancy / breastfeeding

Relative Contraindications

HGH Fragment 176-191

·Absence of human safety data — experimental use only

Semax

·Active psychiatric instability
·Concurrent strong stimulants

05Administration Protocol

Parameter

HGH Fragment 176-191

Semax

1. Route

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Frequency

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.

3. Duration

Animal protocols: 14–19 days. Human duration not established — no published trials.

Morning + early afternoon. Avoid evening (sleep disruption).

4. Storage

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

Refrigerate after reconstitution; light-protected.

5. Detection

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015

Cycle on/off to avoid neurochemical adaptation.

06Stack Synergy

HGH Fragment 176-191

— no documented stacks

Semax

+ Selank

Moderate

View Selank →

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax: 200–600 mcg intranasal · morning + afternoon
Selank: 150–300 mcg intranasal · midday + early evening
Primary benefit: Cognitive enhancement + stress mitigation

Kaplan 2017 Zaderej 2014